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Silvia A. Haueis, Pascale Kränzlin, Joanna Mangana, Phil F. Cheng,
Mirjana Urosevic-Maiwald, Ralph P. Braun, Mitchell P. Levesque,
Reinhard Dummer and Simone M. Goldinger
Brain metastases (brain mets) are frequent in metastatic
melanoma patients. The aim of this study was to investigate
the morphology and progression pattern of brain mets in
melanoma patients treated with BRAF inhibitors (BRAFi)
compared with patients who did not receive targeted
therapy (BRAFi group and control group). The number and
size of brain mets were compared between a baseline and a
comparative MRI at progression. The number of brain mets
was grouped into seven number classes (N= 1–4, N= 5–10,
N= 11–20, N= 21–30, N= 31–40, N= 41–50, and N> 50)
and its difference was reported as the change of class that
occurred. The mean size of the newly developed lesions
was determined by representative measurements and the
evolution of three persisting target lesions was assessed on
the basis of modified RECIST criteria. Of 96 patients
studied, 42 were in the BRAFi group and 54 were in the
control group. Patients under BRAFi treatment had a
significantly greater increase in the number of brain mets,
where the median change of class for the BRAFi compared
with the control group was 2 versus 0 (P< 0.01). The mean
size of the new lesions was smaller in the BRAFi group. Pre-
existing target lesions did not show any prominent or
different patterns of how they evolved in either group. Brain
mets in patients treated with BRAFi showed a progression
pattern characterized by a high propensity to disseminate,
which might reflect an in-vivo manifestation of phenotype
switching in response to targeted therapy, with a
predominance of the invasive/migratory tumor cell
phenotype. Drivers of invasiveness may present promising
targets for therapeutic interventions. Melanoma Res
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Introduction
Melanoma has a high propensity to metastasize to the
brain. Up to 20% of melanoma patients present with
brain metastases (brain mets) at diagnosis of stage IV and
∼ 40–50% ultimately develop them during the course of
their disease [1,2]. Overall, central nervous system
involvement heralds a poor prognosis [3,4].
The introduction of immunotherapy and targeted ther-
apy has changed the standard of care in the treatment of
advanced melanoma. On the basis of the discovery that
40–60% of melanomas harbor a targetable BRAF V600
mutation, a new era of mitogen-activated protein kinase
inhibitors (MAPKi) has been established [5]. Selectively
targeted BRAF-inhibitors (BRAFi, e.g. vemurafenib,
dabrafenib) have shown impressive clinical efficacy and
have led to improved survival in patients with
V600-mutated metastatic melanoma [6,7]. Subsequently,
the superiority of concurrent BRAF/MEK inhibition
(e.g. vemurafenib/cobimetinib, dabrafenib/trametinib)
has been reported in several clinical trials [8,9]. In
patients with brain mets, evidence of clinical activity of
BRAFi is emerging [10,11], and currently available
pooled data show a median overall survival of 7.9 months
in this subset of patients [12]. Although a growing body
of research is evaluating the efficacy and objective
response rates of MAPKi to further determine their role
in patients with brain mets (NCT01378975,
NCT02230306, NCT02039947), the progression pattern
in the brain and the influence of targeted therapies on
this process have not been investigated very extensively
so far. Therefore, the aim of this current study is to
analyze the morphology and pattern of brain mets among
melanoma patients treated with BRAFi and assess
potential differences compared with patients who did not
receive targeted therapies.
Patients and methods
Patient selection and data acquisition
This single-center retrospective analysis was carried out
at the Department of Dermatology of the University
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Hospital Zurich. Patients treated at our institution for
stage IV melanoma with brain mets were identified from
our Melanoma Registry, which records melanoma
patients since 2008, and through our interdisciplinary
oncology board meetings. Eligible patients were 18 years
of age or older, had histologically confirmed stage IV
cutaneous or mucosal melanoma, and at least one intra-
cranial tumor lesion. The study protocol was approved by
the local ethics committee (EK647/KEK-ZH-Nr.
2014–0193).
Patients were divided into two groups on the basis of
whether (BRAFi group) or not (control group) they
received targeted therapy. Targeted therapy included
BRAFi monotherapy and/or BRAFi/MEKi combination
therapy. Electronic medical records were reviewed for
demographical and clinicopathological parameters. Data
extraction included age, sex, primary tumor character-
istics, mutational status, and details of systemic and
locoregional brain therapies.
Definition of baseline and comparative study
To analyze the change in pattern in brain mets in patients
exposed to BRAFi versus those not exposed, two
contrast-enhanced MRI studies of the brain were
compared. The baseline (t1) and comparative image (t2)
for the two different groups were defined as follows: in
the BRAFi group, brain mets evolution under treatment
exposure to targeted therapy was examined. Accordingly,
the last MRI obtained immediately before treatment
initiation with BRAFi (baseline image) was compared
with the last MRI before termination of BRAFi treatment
(comparative image). In the control group, each patient’s
initial and terminal brain mets status was examined. This
was illustrated by the MRI of first radiographical brain
mets detection (baseline image) and the last available
brain MRI in a patient’s disease course (comparative
image).
Pattern analysis: number and size of brain mets
A semiquantitative analysis of the morphological change
of brain mets in terms of the number and size was carried
out. The number of brain mets was stratified into seven
number classes (N= 1–4, N= 5–10, N= 11–20, N= 21–30,
N= 31–40, N= 41–50, and N> 50 metastases). The dif-
ference in the number of metastases between the base-
line and the comparative image was reported by the
change of class that occurred. Possible changes therefore
were a reduction of class (− ), no change of class (= ), and
an increase of 1–6 (+ to ++++++ ) brain mets number
classes.
To investigate how persisting lesions evolved during the
evaluation period, up to three target lesions present and
Table 1 Patient baseline characteristics
BRAFi group Control group
Total number of patients 42 (44) 54 (56)
Age [median (range)] 54 (24–73) 65 (35–86)
Sex
Male 25 (60) 36 (67)
Female 17 (40) 18 (33)
BRAF status
Mutated 42 (100) 6 (11)
Wild type 33 (61)
Unknown 15 (28)
BRAF genotype
V600E 27 (64) 4
V600K 10 (24)
Unknown 4 (10) 1
Othera 1 (2) 1
Localization of primary
Head and neck 9 (21) 10 (19)
Trunk 13 (31) 19 (35)
Upper extremity 7 (17) 7 (13)
Lower extremity 6 (14) 11 (20)
Unknown 7 (17) 7 (13)
Histological subtype
Nodular 15 (36) 14 (26)
Superficial spreading 6 (14) 5 (9)
Acrolentiginous 4 (7)
Lentigo maligna 7 (13)
Mucosal 1 (2) 1 (2)
Other 8 (19) 9 (17)
Unknown 12 (29) 14 (26)
Breslow index (mm)
0.1–1.0 5 (12) 12 (22)
1.01–2.0 9 (21) 9 (17)
2.01–4.0 9 (21) 12 (22)
>4.0 7 (17) 10 (19)
Unknown 12 (29) 11 (20)
Age is reported in years as median age and range. All other variables are reported
in n (%).
aK601E, D594H.
Table 2 Type of systemic therapies received before the evaluation
period for the BRAF inhibitor and the control group
Systemic therapies before t1 BRAFi group (N=42) Control group (N=54)
No systemic therapy 32 (76) 34 (63)
Chemo only 7 (17) 7 (13)
Immuno only 2 (5) 4 (7)
Chemo+ immuno 6 (11)
Chemo+mki 2 (4)
Chemo+ immuno+mki 1 (2) 1 (2)
Variables are reported in n (%).
Immunotherapy included ipilimumab, nivolumab, pembrolizumab, and tremeliumab.
Multikinase inhibitor therapy included sorafenib, pazopanib, and imatinib.
BRAFi, BRAF inhibitor; Chemo, chemotherapy; Immuno, immunotherapy; mki,
multikinase inhibitor therapy.
Table 3 Locoregional brain therapies administered to the BRAF
inhibitor and the control group during the evaluation period
Brain therapies during t1–t2
BRAFi group
(N=42)
Control group
(N=54)
No brain therapy 24 (57) 7 (13)
Surgical resection 2 (5) 1 (2)
Radiation therapy (WBRT, SRS or
both)
13 (31) 22 (41)
Combination of resection and
radiation
3 (7) 24 (44)
Variables are reported in n (%).
t1–t2 represents the evaluation period between the baseline and the
comparative image.
BRAFi, BRAF inhibitor; SRS, stereotactic radiosurgery; WBRT, whole-brain
radiation therapy.
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reproducibly measurable in both baseline and compara-
tive images were defined, and their largest sum of dia-
meter was measured. The difference in the largest sum of
diameter was calculated and then reported as stable dis-
ease, progressive disease, partial response, or complete
response according to a modified application of the
RECIST 1.1 criteria. An estimate of the mean size of the
newly developed brain mets at t2 was made by measuring
up to five lesions considered to be representative of the
new lesion’s predominant size. All analyses were carried
out by the same investigator.
Statistical analysis
For statistical analysis, Microsoft Excel 2011 (version 14;
Microsoft Corporation, Redmond, Washington, USA) and
SPSS (version 22; IBM, Armonk, New York, USA) soft-
ware was used. Descriptive results were reported as
numbers, percentages, mean, and median. Data were
analyzed using the Mann–Whitney U-test and the
Student t-test. A P-value below 0.05 was considered to
indicate statistical significance.
Results
Patient, disease, and treatment characteristics
A total of 96 patients were included for analysis and
patient baseline characteristics are reported in Table 1.
In the BRAFi group, 32 (76%) patients received targeted
therapy upfront, whereas the remaining 24% had other
systemic therapies before BRAFi treatment. In the con-
trol group, 20 (37%) patients received systemic therapies
before the evaluation period. Details on the systemic
therapies patients received before the evaluation period
are shown for each group in Table 2.
During the evaluation period, patients in the BRAFi group
received either BRAFimonotherapy, in 83% (all vemurafenib,
N=35), combination therapy, in 7% (vemurafenib/cobimeti-
nib, N=1, encorafenib/binimetinib, N=2), or monotherapy
Fig. 1
Number of brain mets. These pie charts show the relative distribution and longitudinal evolution of the number of brain mets (categorized in number
classes) for both patients who were treated with BRAF inhibitors (BRAFi group) and those who did not receive targeted therapy (control group). N,
number of brain metastases. (a) Number class at baseline, BRAFi group. (b) Number class at comparison, BRAFi group. (c) Number class at baseline,
control group. (d) Number class at comparison, control group. Brain mets, brain metastases.
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with vemurafenib, followed by combination therapy, in
10% (vemurafenib/cobimetinib, N=2, dabrafenib/trametinib,
N=2). Patients in the control group received systemic ther-
apy, 89%, during the evaluation period (chemotherapy alone,
N=21, immunotherapy alone, N=13, multikinase inhibitor
alone, N=1, chemotherapy and immunotherapy, N=7, che-
motherapy and multikinase inhibitor, N=6).
Locoregional brain therapies including surgical resection,
radiation therapy (stereotactic radiosurgery and/or whole-
brain radiation therapy), or a combination of both surgical
resection and radiation therapy were more frequently
used in the control group than in the BRAFi group (87
and 43%, respectively). Details on brain therapies admi-
nistered during t1 and t2 are shown for each group in
Table 3.
The median observation time between the baseline and
comparative image (t1–t2) was similar in both groups, with
5.8 (range: 1.6–20.7) months in the BRAFi group and 5.3
(range: 0.6–38.2) months in the control group. The
median treatment duration with targeted therapy in the
BRAFi group was 5.8 (range: 1.9–24.4) months.
Number of brain mets
The majority of patients in both the BRAFi and control
groups had 1–4 brain mets at baseline (62 and 78%,
respectively). More patients in the BRAFi group already
had more than 10 brain mets at baseline (31 vs. 9%). The
distributions of brain mets present at baseline and com-
parative images are shown for each group in Fig. 1.
In the comparative MRI, there was a significantly higher
increase in the number of brain mets in the BRAFi
compared with the control group (P< 0.01). The majority
(60%) of the patients in the BRAFi group showed an
increase of more than one number class, whereas only
15% in the control group showed an increase of more
than one number class (Fig. 2a). The patients in the
BRAFi group showed a median increase of two number
classes, whereas patients in the control group remained in
the same class (median class switch of 2 vs. 0, P< 0.01,
Fig. 2b).
No change in class or even a reduction in class was more
frequently observed in the control group than in the
BRAFi group (44 and 26% vs. 23 and 2%, respectively).
Size of brain mets
Pre-existing target lesions did not show any prominent or
different patterns of how they evolved in either group. A
higher percentage of patients in the BRAFi group
showed a partial response of their target lesions (29 vs.
13%). Fourteen (26%) patients in the control group
showed a complete response associated with a reduction
of class, but only one patient in the BRAFi group.
New emerging lesions measured at t2 were in general
smaller in the BRAFi group (mean size 5.9 mm) com-
pared with the control group (mean size 7.4 mm). This
difference was not statistically significant (P= 0.15).
Discussion
BRAF-targeted therapies have become a very important
component in the treatment of patients with BRAF-
mutated metastatic melanoma, including patients with
brain mets. To our knowledge, this is the first study to
focus on the morphology and pattern of brain mets pro-
gression in melanoma patients treated with BRAFi
compared with patients not exposed to such therapies.
Fig. 2
Brain mets number class switch. (a) The longitudinal change in number
of brain mets grouped into classes is shown with the respective
percentages for both the BRAFi and the control group. ‘− ’: reduction of
class. ‘= ’: no change in class. ‘+ ’ to ‘++++++ ’: increase in 1–6
brain mets number classes. (b) Median brain mets number class switch
between the baseline and comparative image for the BRAFi and the
control group: Boxplot, P<0.01. BRAFi, BRAF inhibitors; Brain mets,
brain metastases.
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Our data indicated that patients under BRAFi frequently
showed a marked increase in the number of brain mets
during targeted therapy. MRIs at the time of comparison
often showed more multiple and smaller brain lesions
than before initiation of BRAFi treatment at baseline
and, in some cases, showed innumerable contrast-
enhancing punctate lesions (Fig. 3), indicative of a mili-
ary, disseminated distribution pattern of brain mets. In
the control group, such intracranial disease courses were
far less likely to occur and the majority of patients did not
even experience an increase in the number class of pre-
sent brain mets at all.
These results are intriguing because they suggest an
unusual dissemination pattern of brain mets under
BRAFi treatment and consequently, the question arises
whether this pattern is unique to the brain or might
reflect a general effect of BRAFi treatment. Azer et al.
[13] investigated patterns of response and progression
assessed by disease-site (intracranial vs. extracranial) in
Fig. 3
Brain metastasis (brain mets) evolution on MRI. Axial t1-weighted gadolinium-enhanced MRIs of the brain of two BRAF mutant melanoma patients
treated with a selective BRAF inhibitor (exemplary for the BRAFi group) showing a significant increase in the number of brain mets between the
baseline (left) and the comparative image (right). Each patient is shown as a horizontal line.
Brain mets progression pattern under BRAFi Haueis et al. 5
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23 patients with melanoma brain mets treated with
dabrafenib. They concluded that there was no dominant
site (intracranial vs. extracranial) or pattern (new vs.
existing lesions) of disease progression and site-specific
response was concordant in 71% [13]. In contrast, Seifert
et al. [14] found in a retrospective study that response to
vemurafenib was indeed dependent on the anatomical
site and complete or partial response was particularly low
in the brain. In addition, the brain was the most common
site for new metastases to develop [14]. Similarly, there
was considerable remission of extracerebral disease, but
intracranial metastases developed or progressed in a ser-
ies of patients [15].
Recently, many researchers have intensively investigated
the various mechanisms driving tumor progression and
drug resistance in melanoma. One model that has been
able to link the changes observed in cellular behavior and
molecular biology during metastatic progression and has
increasingly been invoked is the phenotype switching
model. It is based on the characterization of different
gene expression signatures that define two populations of
melanoma cells, distinctive by showing either a more
invasive or a proliferative phenotype [16,17]. These
transcriptional states are interchangeable programs
between which melanoma cells switch back and forth,
catalyzing repeated episodes of dissemination and
tumorigenesis, where the dynamics of this process are
markedly influenced by local microenvironmental factors
[17,18]. The transition from a proliferative to an invasive
phenotype shares many features of epithelial-to-
mesenchymal transformation and is associated with a
characteristic cell morphology switch from predominantly
rounded to elongated cells [19–21]. In line with other
researchers, we believe that melanoma cells use pheno-
type switching as an escape mechanism to targeted
therapy as it has been observed that proliferative
melanoma cells can acquire invasive features upon
MAPKi, and as a result, not only become less susceptible
to growth inhibition but also have greater ability to
metastasize [19,22,23]. Apart from this, there is growing
literature stating an increased activation of the AKT-
PI3K pathway in melanoma brain mets compared with
other distant metastatic sites [15,24], and melanoma cells
stimulated by astrocyte-conditioned medium showed
higher AKT activation and invasiveness, adding evidence
that extrinsic factors in the brain microenvironment
may induce these brain-specific molecular alterations
[14,15,25]. This supports the hypothesis that the tumor
microenvironment differs between the body and the
brain and that this type of resistance mechanism to
BRAFi could be specific to the brain. Yet, in autopsy
studies of some of our BRAF-mutated melanoma
patients, we have observed a similar disseminated
metastatic spread in other organs than the brain,
including the lung and the liver.
There are limitations in this study and its retrospective
nature is certainly one of them. Tailored to each patient’s
individual needs, the two groups are heterogeneous in
the systemic and local brain treatments received before
and during the evaluation period. Apart from the fact that
the group allocation was primarily dependent on the
patient’s BRAF mutational status, t1 and t2 represented
logical time points on the basis of exposure to a specific
therapy in the BRAFi group, whereas a slightly different
timeline was observed in the control group. In addition,
the semiquantitative approach by grouping the number
of brain mets in classes and reporting class switches
instead of exact numbers and differences limits accuracy.
Still, we are convinced that our results show clear and
reliable differences between the two groups.
Conclusion
Patients under BRAFi showed a distinct pattern of pro-
gression in the brain. It seems that BRAFi therapy can
facilitate metastatic dissemination in the brain, leading to
a miliary pattern of brain mets presenting with multiple
small punctate lesions in MRIs. This might reflect an in-
vivo manifestation of phenotype switching in melanoma
progression and suggests the predominance of an inva-
sive/migratory tumor cell phenotype. Therefore, drivers
of invasiveness may present promising targets for ther-
apeutic interventions.
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